Last update Dec. 18, 2020


Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Hemostatic drug which has a possible protective effect on the capillary wall along with correction of altered platelet adhesion.
It is used in Menometrorrhagia (Lethaby 2013), prophylaxis on surgical wounds and neonatal intraventricular hemorrhage without a solid evidence of its effictiveness (Hunt 2010, Kuperman 2015).
It is orally, intramuscularly and intravenously administered every 4 - 6 hours for 3 - 4 days.

At latest update relevant published data on excretion into breast milk were not found.

Its high capacity of binding to plasma proteins makes it unlikely a excretion into breast milk.

Due to low frequency and mildness of eventual side effects and/or absence of interference with coagulation mechanisms, seems unlikely this product would affect breastfeeding or the infant.


We do not have alternatives for Etamsylate.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Etamsylate is also known as

Etamsylate in other languages or writings:


Etamsylate belongs to this group or family:


Main tradenames from several countries containing Etamsylate in its composition:


Variable Value Unit
Molecular weight 263 daltons
Protein Binding 95 %
Tmax 4 hours
1.9 - 3.7 hours


  1. Kuperman AA, Brenner B, Kenet G. Intraventricular haemorrhage in preterm infants--can we improve outcome by addressing coagulation? J Matern Fetal Neonatal Med. 2015 Abstract
  2. Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013 Abstract
  3. Unichima. Etamsylate. Drug Summary. 2012 Full text (in our servers)
  4. Hunt R, Hey E. Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants. Cochrane Database Syst Rev. 2010 Abstract
  5. AEMPS. Etamsilato. Ficha técnica. 2010 Full text (in our servers)
  6. MEPPO. Etamsylate Drug Summary. 2010 Full text (in our servers)
  7. Arora YR, Manford ML. Operative blood loss and the frequency of haemorrhage associated with adenotonsillectomy in children: a double-blind trial of ethamsylate. Br J Anaesth. 1979 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM